Pulmonary Congestion and Left Ventricular Dysfunction after Myocardial Infarction: Insights from the PARADISE-MI Trial

Mark C. Petrie; Jean L. Rouleau; Brian Claggett; Karola Jering; Peter Van Der Meer; Lars Køber; Zi Michael Miao; Eldrin Lewis; Christopher Granger; Carmine G. De Pasqulae; Douglas Mann; Philippe Gabriel Steg; Aldo Maggioni; Offer Amir; Marty Lefkowitz; Eugene Braunwald; Scott D. Solomon; John J.V. McMurray; Marc A. Pfeffer

doi:10.1161/CIRCULATIONAHA.123.066163

Pulmonary Congestion and Left Ventricular Dysfunction after Myocardial Infarction: Insights from the PARADISE-MI Trial

Mark C. Petrie, Jean L. Rouleau, Brian Claggett, Karola Jering, Peter Van Der Meer, Lars Køber, Zi Michael Miao, Eldrin Lewis, Christopher Granger, Carmine G. De Pasqulae, Douglas Mann, Philippe Gabriel Steg, Aldo Maggioni, Offer Amir, Marty Lefkowitz, Eugene Braunwald, Scott D. Solomon, John J.V. McMurray, Marc A. Pfeffer

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

The PARADISE-MI ([Prospective ARNI vs ACE Inhibitors Trial to Determine Superiority in Reducing Heart Failure Events After MI] URL: https://clinicaltrials.gov; Unique identifier: NCT02924727) trial investigated whether sacubitril/valsartan improved outcomes compared to ramipril after acute myocardial infarction (MI).1 Sacubitril/valsartan did not reduce the risk of the primary composite outcome of cardiovascular death, outpatient development of heart failure (HF), or hospitalization for HF compared to ramipril.

Original language	English
Pages (from-to)	335-338
Number of pages	4
Journal	Circulation
Volume	149
Issue number	4
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.123.066163
Publication status	Published - 23 Jan 2024

Keywords

heart failure
myocardial infarction
ramipril
valsartan
ventricular dysfunction, left

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/CIRCULATIONAHA.123.066163Licence: In Copyright

Cite this

Petrie, M. C., Rouleau, J. L., Claggett, B., Jering, K., Van Der Meer, P., Køber, L., Miao, Z. M., Lewis, E., Granger, C., De Pasqulae, C. G., Mann, D., Steg, P. G., Maggioni, A., Amir, O., Lefkowitz, M., Braunwald, E., Solomon, S. D., McMurray, J. J. V., & Pfeffer, M. A. (2024). Pulmonary Congestion and Left Ventricular Dysfunction after Myocardial Infarction: Insights from the PARADISE-MI Trial. Circulation, 149(4), 335-338. https://doi.org/10.1161/CIRCULATIONAHA.123.066163

@article{03f7d6a82f624e6da760d6f2957d960c,

title = "Pulmonary Congestion and Left Ventricular Dysfunction after Myocardial Infarction: Insights from the PARADISE-MI Trial",

abstract = "The PARADISE-MI ([Prospective ARNI vs ACE Inhibitors Trial to Determine Superiority in Reducing Heart Failure Events After MI] URL: https://clinicaltrials.gov; Unique identifier: NCT02924727) trial investigated whether sacubitril/valsartan improved outcomes compared to ramipril after acute myocardial infarction (MI).1 Sacubitril/valsartan did not reduce the risk of the primary composite outcome of cardiovascular death, outpatient development of heart failure (HF), or hospitalization for HF compared to ramipril.",

keywords = "heart failure, myocardial infarction, ramipril, valsartan, ventricular dysfunction, left",

author = "Petrie, {Mark C.} and Rouleau, {Jean L.} and Brian Claggett and Karola Jering and {Van Der Meer}, Peter and Lars K{\o}ber and Miao, {Zi Michael} and Eldrin Lewis and Christopher Granger and {De Pasqulae}, {Carmine G.} and Douglas Mann and Steg, {Philippe Gabriel} and Aldo Maggioni and Offer Amir and Marty Lefkowitz and Eugene Braunwald and Solomon, {Scott D.} and McMurray, {John J.V.} and Pfeffer, {Marc A.}",

year = "2024",

month = jan,

day = "23",

doi = "10.1161/CIRCULATIONAHA.123.066163",

language = "English",

volume = "149",

pages = "335--338",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams & Wilkins",

number = "4",

}

Petrie, MC, Rouleau, JL, Claggett, B, Jering, K, Van Der Meer, P, Køber, L, Miao, ZM, Lewis, E, Granger, C, De Pasqulae, CG, Mann, D, Steg, PG, Maggioni, A, Amir, O, Lefkowitz, M, Braunwald, E, Solomon, SD, McMurray, JJV & Pfeffer, MA 2024, 'Pulmonary Congestion and Left Ventricular Dysfunction after Myocardial Infarction: Insights from the PARADISE-MI Trial', Circulation, vol. 149, no. 4, pp. 335-338. https://doi.org/10.1161/CIRCULATIONAHA.123.066163

TY - JOUR

T1 - Pulmonary Congestion and Left Ventricular Dysfunction after Myocardial Infarction

T2 - Insights from the PARADISE-MI Trial

AU - Petrie, Mark C.

AU - Rouleau, Jean L.

AU - Claggett, Brian

AU - Jering, Karola

AU - Van Der Meer, Peter

AU - Køber, Lars

AU - Miao, Zi Michael

AU - Lewis, Eldrin

AU - Granger, Christopher

AU - De Pasqulae, Carmine G.

AU - Mann, Douglas

AU - Steg, Philippe Gabriel

AU - Maggioni, Aldo

AU - Amir, Offer

AU - Lefkowitz, Marty

AU - Braunwald, Eugene

AU - Solomon, Scott D.

AU - McMurray, John J.V.

AU - Pfeffer, Marc A.

PY - 2024/1/23

Y1 - 2024/1/23

N2 - The PARADISE-MI ([Prospective ARNI vs ACE Inhibitors Trial to Determine Superiority in Reducing Heart Failure Events After MI] URL: https://clinicaltrials.gov; Unique identifier: NCT02924727) trial investigated whether sacubitril/valsartan improved outcomes compared to ramipril after acute myocardial infarction (MI).1 Sacubitril/valsartan did not reduce the risk of the primary composite outcome of cardiovascular death, outpatient development of heart failure (HF), or hospitalization for HF compared to ramipril.

AB - The PARADISE-MI ([Prospective ARNI vs ACE Inhibitors Trial to Determine Superiority in Reducing Heart Failure Events After MI] URL: https://clinicaltrials.gov; Unique identifier: NCT02924727) trial investigated whether sacubitril/valsartan improved outcomes compared to ramipril after acute myocardial infarction (MI).1 Sacubitril/valsartan did not reduce the risk of the primary composite outcome of cardiovascular death, outpatient development of heart failure (HF), or hospitalization for HF compared to ramipril.

KW - heart failure

KW - myocardial infarction

KW - ramipril

KW - valsartan

KW - ventricular dysfunction, left

UR - http://www.scopus.com/inward/record.url?scp=85182768315&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.123.066163

DO - 10.1161/CIRCULATIONAHA.123.066163

M3 - Article

C2 - 38252738

AN - SCOPUS:85182768315

SN - 0009-7322

VL - 149

SP - 335

EP - 338

JO - Circulation

JF - Circulation

IS - 4

ER -

Pulmonary Congestion and Left Ventricular Dysfunction after Myocardial Infarction: Insights from the PARADISE-MI Trial

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this